Axonics, Inc.

Good day, and thank you for standing by. Welcome to Exonix Q3 2022 results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Neil Ballacher. Please go ahead.

Thank you. Good afternoon and thank you for joining Exonix's third quarter 2022 results and update call. Presenting on today's call are Raymond Cohen, Chief Executive Officer, and Dan Deren, President and Chief Financial Officer. Before we begin, I'd like to remind listeners that statements made on this conference call that relate to future plans, events, prospects, or performance are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. While these forward-looking statements are based on management's current expectations and beliefs, these statements are subject to a number of risks, uncertainties, assumptions, and other factors that could cause results to differ materially from the expectations expressed on this conference call. These risks and uncertainties are disclosed in more detail in Axonix's filings with the Securities and Exchange Commission, all of which are available online at www.sec.gov. Listeners are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date, October 31st, 2022. Except as required by law, Exonix undertakes no obligation to update or revise any forward-looking statements to reflect new information, circumstances, or unanticipated events that may arise. With that, I'd like to now turn the call over to Ray.

Thanks, Neil. I'd like to welcome everyone joining this call this afternoon. And before I begin with my remarks, I want to note two really notable events. That is, today on October 31st, Halloween, is exactly four years since the date of our initial public offering. So it's kind of a big day for us today with our four-year anniversary. And moreover, On November the 1st, which would be tomorrow, was the date of our first U.S. implant of a sacral nomodulation device in America. So October 31st, November 1st, these are dates that they really resonate with us at Exonix. So getting on to the business at hand, we're really proud of our third quarter 2022 financial results in which Exonix generated record total revenue of $70.4 million in This is now the second quarter in a row in which our total revenue has grown by over 50% year-over-year and demonstrates the growing demand for Exonix's best-in-class incontinence products. More specifically, cyclonal modulation revenue was $56.9 million, representing an increase of 42% compared to the same period of last year. This record level of synchronal modulation revenue is being driven by a combination of market expansion and continued share capture from the incumbent. The broad U.S. commercial launch of our recharge-free S&M system, as we've dubbed the Exonix F15, has been very well received by implanting physicians and continues to exceed even our own high expectations. Now turning to BulkMed, revenue in the third quarter was $13.5 million, including $11 million, which was generated in the United States. Record results were driven by solid reorder rates from existing accounts and the onboarding of new accounts. We expect approximately 50,000 women will have their stress urinary incontinence symptoms treated with BulkMed worldwide during calendar year 2022. We're humbled by this result and believe we are still scratching the surface of what is possible in this large and highly underserved and undertreated female stress urinary incontinence market. Based on this past quarter's strong results, we are raising our fiscal year 2022 total company revenue guidance to $262 million, which represents an increase of 45% compared to 2021. Now, I'm going to provide some additional business updates prior to the Q&A session. However, I'd like to turn the call over to Dan for his detailed review of third quarter financial results. So, Dan, take it away.